Cleveland State University

EngagedScholarship@CSU
Undergraduate Research Posters 2018

Undergraduate Research Posters

2018

Increasing the Efficacy of Doxorubicin Against Breast Cancer
Jovana Hanna
Cleveland State University

Jung-Suk Choi
Cleveland State University

Follow this and additional works at: https://engagedscholarship.csuohio.edu/u_poster_2018
Part of the Chemistry Commons

How does access to this work benefit you? Let us know!
Recommended Citation
Hanna, Jovana and Choi, Jung-Suk, "Increasing the Efficacy of Doxorubicin Against Breast Cancer" (2018).
Undergraduate Research Posters 2018. 28.
https://engagedscholarship.csuohio.edu/u_poster_2018/28

This Book is brought to you for free and open access by the
Undergraduate Research Posters at
EngagedScholarship@CSU. It has been accepted for
inclusion in Undergraduate Research Posters 2018 by an
authorized administrator of EngagedScholarship@CSU. For
more information, please contact library.es@csuohio.edu.

Poster 28

Increasing the Efficacy of Doxorubicin Against Breast Cancer
College of Sciences and Health Professions
Student Researchers: Jovana Hanna and Jung-Suk Choi1
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Abstract
In the United States, breast cancer accounts for one in three cancer diagnoses in women,
making it the most common type of cancer in women. One important chemotherapeutic
agent used to treat breast cancer is doxorubicin, an anthracycline compound that causes
cell death by damaging DNA in addition to producing reactive oxygen species.
Previously, the Berdis lab developed an artificial nucleoside analog designated 5-NIdR
that improves the efficacy of DNA damaging agents used against brain cancer. This
nucleoside works by inhibiting the replication of damaged DNA created by certain
chemotherapeutic agents. In this project, we tested the ability of 5-NIdR to increase the
efficacy of doxorubicin in the treatment of breast cancer. This was accomplished by
comparing the effects of doxorubicin in the absence and presence of 5-NIdR using
MCF-7 breast cancer cells and non-cancerous fibroblasts as models. Our studies show
that breast cancer cells are highly resistant to doxorubicin, displaying an LD50 value of
840 nM which is 8-fold higher than that measured against non-cancerous fibroblasts
(LD50 = 105 nM). Combining 5-NIdR with doxorubicin kills more cells compared to
treatment with either doxorubicin or 5-NIdR used alone.
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